RT Journal Article
T1 Novel therapeutic strategies for atopic dermatitis: Biomarker modulation and clinical implications. A systematic review
A1 Moreiras Arias, Noelia
A1 Nieto Fontarigo, Juan José
A1 Salgado Castro, Francisco Javier
A1 González Vilas, Daniel
A1 Paredes Suárez, Carmen
A1 Combo García, Enma
A1 Rodríguez Otero, Carmen
A1 Flórez, Ángeles
K1 Atopic dermatitis
K1 Biomarkers
K1 Biologic therapy
K1 JAK inhibitors
K1 Omics
AB Advances in the understanding of atopic dermatitis (AD) pathogenesis have driven the development of innovative systemic therapies targeting key immunologic pathways. This systematic review summarizes current evidence on the impact of biologic agents, Janus kinase (JAK) inhibitors, and other emerging treatments on AD-related biomarkers and their correlation with clinical outcomes. A comprehensive literature search was conducted across PubMed, Embase, Scopus, and Web of Science for studies published between 2014 and 2024. Eighty studies met the inclusion criteria. Dupilumab was the most extensively investigated therapy, followed by tralokinumab, JAK inhibitors, and novel agents such as amlitelimab, stapokibart, and tezepelumab. Across drug classes, consistent reductions in CCL17/TARC, LDH, and total IgE levels were observed, generally paralleling clinical improvement in EASI and SCORAD scores. Transcriptomic and proteomic analyses revealed normalization of Th2/Th22 inflammatory signatures and restoration of barrier-related gene expression, while microbiome studies showed a reduction in Staphylococcus aureus colonization. Despite these advances, the heterogeneity of study designs and analytical techniques limits the comparability of results. CCL17 and LDH currently represent the most reliable biomarkers associated with disease severity and treatment response, although their limited specificity restricts clinical applicability. Future research should aim to validate integrated biomarker panels combining immunologic, transcriptomic, and microbiomic data to enable precision medicine approaches in atopic dermatitis management.
PB Springer Nature
SN 1080-0549
YR 2026
FD 2026-01-29
LK https://hdl.handle.net/10347/47227
UL https://hdl.handle.net/10347/47227
LA eng
NO Moreiras-Arias, N., Nieto-Fontarigo, J. J., Salgado, F. J., González-Vilas, D., Paredes-Suárez, C., Combo-García, E., Rodríguez-Otero, C., & Flórez, Á. (2026). Novel Therapeutic Strategies for Atopic Dermatitis: Biomarker Modulation and Clinical Implications. A Systematic Review. Clinical Reviews in Allergy & Immunology, 69(1), Article 4. https://doi.org/10.1007/s12016-025-09129-z
NO Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This work was funded by the Carlos III Health Research Fund (PI25/00440; Molecular Analysis and Cellular Profiling in Atopic Dermatitis (MAP-AD): Identifying Biomarkers and Therapeutic Targets with Focus on Inflammation and Fibrosis). The publication is part of the grant RYC2021-032676-I financed by MCIN/AEI/10.13039/501100011033 and by the European Union’s Next Generation EU/PRTR.
DS Minerva
RD 23 may 2026